Trial Profile

Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sacituzumab govitecan (Primary) ; Trilaciclib (Primary)
Indications Advanced breast cancer; Male breast cancer; Myelosuppression; Triple negative breast cancer
Focus Therapeutic Use
Acronyms ASCENT
Sponsors G1 Therapeutics

29 Jan 2025 Status changed from completed to discontinued.
08 Aug 2024 Status changed from active, no longer recruiting to completed.
04 Jun 2024 Results ( As of January 2, 2024, n=30) assessing safety and efficacy of trilaciclib prior to SG in mTNBC presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com